Carfilzomib, which is used to treat multiple myeloma, has been found to increase the risk of cardiovascular disease (CVD). In order to assess the connection between carfilzomib and cardiovascular adverse events (CVAE), researchers from the Abramson Cancer Center of the University of Pennsylvania reviewed 24 clinical trials that included 2,594 patients with multiple myeloma. The results, published in JAMA Oncology, showed that 18% of multiple myeloma patients taking carfilzomib experienced serious heart conditions such as hypertension, heart failure, heart attacks or arrhythmia.
